Press Releases

Oral Formulation Clinical Data Currently Anticipated by Year End Nov 08, 2018, 07:30 ET CRANBURY, N.J., Nov. 8, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced Phase 1, first-in-human results of […]

Nov 07, 2018, 16:15 ET CRANBURY, N.J., Nov. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2019 operating results on Tuesday, November 13, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

Vyleesi™ New Tradename for Bremelanotide PDUFA Target Action Date of March 23, 2019 for Vyleesi Teleconference and Webcast to be held on September 13, 2018 CRANBURY, N.J., Sept. 13, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin

Sep 07, 2018, 16:00 ET CRANBURY, N.J., Sept. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by

Jun 25, 2018, 04:56 ET CRANBURY, N.J., June 25, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has been added to the Russell 3000® Index as part of the annual

PDUFA Target Action Date March 23, 2019 Triggers Milestone Payment to Palatin of $20 Million CRANBURY, N.J., June 4, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that the U.S. Food and

May 15, 2018, 07:30 ET CRANBURY, N.J., May 15, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2018. Recent Highlights Bremelanotide – Under

May 10, 2018, 04:30 ET CRANBURY, N.J., May 10, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management

PL-8177 Evaluated in Animal Models of Inflammatory Bowel Disease and Autoimmune Uveitis; PL-8331 Evaluated in an Animal Model of Dry Eye CRANBURY, N.J., May 9, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential,

CRANBURY, N.J., April 3, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced the presentation of a poster on preclinical studies of an oral formulation of PL-8177, a selective melanocortin receptor 1